Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BI 14332 CL in Type 2 Diabetes
NCT02212925Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2006
- Primary completion
- Mar 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 14332 CL with Placebo (2 arms). Primary endpoints: Number of patients with adverse events, Number of patients with clinically significant findings in vital signs and 3 more. Started Nov 2006; status: terminated.
02
Drugs
BI 14332
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02212925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212925.